跳至主要内容
临床试验/EUCTR2009-011881-27-DE
EUCTR2009-011881-27-DE进行中(未招募)不适用

Changes of cerebral spinal fluid APPSa levels under oral therapy with acitretin 30 mg daily in patients with mild to moderate Alzheimer’s disease: a multicenter prospective randomised placebo-controlled parallel-group study. - Alzheimer´s Disease Acitretin Medication (ADAM)

niversity Medical Center of the Johannes Gutenberg-University Mainz0 个研究点开始时间: 2010年1月20日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • mild to moderate AD (NINCDS-ADRDA criteria)
  • MMSE according to Folstein: 27-14 points
  • Geriatric Depression Scale = 14
  • age = 50 years
  • ability of subject to understand character and individual consequences of clinical trial
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 38
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 38

排除标准

  • hereditary cognitive impairment
  • known history of brain injuries
  • Insufficient German language skills
  • actual treatment with other potential disease modifying drugs of AD
  • multimorbidity or significant organ (esp. liver or renal) dysfunction
  • evidence of Non-AD neurodegenerative disorder (e.g. Parkinson)
  • contraindication to acitretin such as osteoporosis, hypoalbuminaemia

研究者

发起方
niversity Medical Center of the Johannes Gutenberg-University Mainz

相似试验